Exit Science matches your emerging technology with the right market and funders. Together, we build founder-led, evidence-based, effective, and attainable exit-focused business plans.
Transforming opportunity
into exits
What we do together.
Kick-start your executive strategy and bolster your operational team and execution with Exit Science. We bring the evidence and experience you need to identify and align your plans with an optimal market and exit trajectory.
Our team of subject-matter experts and advisors advise and support motivated and willing founders through a process of business and technical planning. We employ proven risk reduction and optimal product-market fit research and methodology. The methodology we share with you is based on our team’s collective successful exits, decades of commercialization experience in relevant industries and start-ups.
01
FOCUS - Identify and Optimize your product-market fit
Together, we…
Develop commercialization-ready, exit-focused plans, supporting sale via merger or acquisition, tech license, scale to commercial, or strategic partnership
Uncover and analyze relevant market data to de-risk a -realistic path-to-exit
Our experts advise on:
-
Market research
-
Corporate intelligence
-
Market analysis and forecasting
-
Commercialization planning and support
-
Product/market fit analysis and recommendations
02
OPERATIONLIZE – Operational planning and execution of your plans
Our team works with yours to kick-start building and executing your plans.
We start to:
-
Outline, build, and implement integrated and aligned business and technical commercialization plans
-
Seamlessly marry your technical differentiators with valuable markets ready to buy your solution.
We align your plans on:
-
Operationalization
-
Human and physical resources
-
Product development
-
Manufacturing
-
Supply chain
-
Regulatory
03
FUND – Share tools and direction to engage and enroll funders
Exit Science maximizes your exit opportunity by providing you with strategic investor relations support by:
Detailing credible, measurable, and visionary investor stories based on the realistic and reasonable exit scenarios we built together
Your investor story is supported by the milestone-based product development and commercialization plans.
Our experts have deep experience in:
-
Mergers and acquisitions
-
Product licensing
-
Strategic partnerships
Working together, on your Exit.
You get access to an unmatched team of global resources and experienced support, customized for your needs.
We build a bespoke, integrated team suited for your business goals. With everyone focused on optimizing the value of your technology.
Your senior team:
Gets augmented by ours to produce and execute a de-risked company life-cycle all the way to exit.
01
Is allowed to focus on leadership and execution.
02
With our help, build methodical, evidence-based, and milestone-driven plans, giving investors confidence in your ability to execute.
03
Aligns on detailed plans and support materials supporting appropriate capital raise tranches to realistically support your executional plans.
04
Exits the program confidently able to answer key questions for investors, funders, and strategic partners, based on common due diligence requirements.
05
How and how long.
We employ a milestone-based, two-phase process to establish your exit options. Phase 1 starts with a detailed market analysis. Then our team recommends the most suitable product-market fit and executional path to your optimal exit.
For Phase 2, we turn the recommendation into action. We build detailed plans together and quickly move to operationalize those plans. We identify the right resources required for success including:
-
People,
-
Facilities and equipment,
-
Most importantly, the right kind and amount of capital to execute your plans as intended.
PHASE 1
Opportunity optimization
1
ENGAGEMENT
Understand your current plans, operational capacity and exit goals.
2
ANALYSIS
Examine 3–5 high potential commercial markets for your technology to compare evidence and uncover the optimal exit opportunity.
3
OPPORTUNITY
Recommend and provide tangible evidence to support the optimal opportunity for your technology along with a statement of work outlining Phase 2.
MONTH 1
Engagement / Evidence gathering
Technical/product requirements/gaps
Commercialization data and analysis
ESTABLISH
-
Problem, Solution & Market Data
-
Management Team roles, responsibilities, gaps
-
Recommended commercialization plan and Phase 2 SOW
MONTHS 2/3
Evidence-based commercialization recommendations/ Phase 2 SOW
Business and commercial assessment
Technical and product development assessment
Business model and market recommendation
EVALUATION CRITERIA
-
Is there a strong business case?
-
Is the recommended model viable, the exit vision reasonable, and are proposed markets accessible?
-
What does your team need to execute?
PHASE 2
Investment attraction and operational implementation
1
EXIT-READY PLANNING
Milestone-focused, evidence-based, cross-functionally integrated plans designed to answer key due diligence questions credibly and confidently.
2
INVESTOR EXIT STORY
Detailed cross functional plans married with evidence and experience-based forecasting and modelling provide investors and partners with a realistic financing roadmap to an optimal exit.
3
OPERATIONAL EXECUTION
Our experienced executive-level team supports and augments your core team finding and onboarding the right resources – human and physical – to achieve your milestones. We help ensure your team delivers on its promises to investors and partners on your path to exit.
MONTHS 3/4
Integrated cross-functional planning & execution
Business and technical planning
Establish funding and plan milestones
Prepare to fill resource gaps
MONTHS 4/5
Execution, Plan Finalization & Exit Path
Finalize cross-functional plans
Begin execution of resource plan
Establish Investor targets
Establish investor presentation
Implement Due Diligence checklist
MONTHS 6/10
Execution and Operationalization
Finalize operational plans
Finalize investor package
Identify investment targets
Populate investor data room and material support
Operational plans approval and transfer
EVALUATION CRITERIA
-
Is there a strong business case?
-
Is the recommended model viable, the exit vision reasonable, and are proposed markets accessible?
-
What does your team need to execute?
Who you work with.
Your team and emerging technology are supported and guided by an unmatched team of experienced, international and local executives and advisors working to accelerate your planning and growth.
We believe in TEAM. No founder exits without help. No single consultant can deliver the broad expertise required to build and execute detailed cross-functional plans from product design to commercialization.
We assembled a team of global experts to work alongside you on bespoke and believable exit plans.
Business Intelligence, Planning and Commercialization
Technical strategy, Operational execution
Marc Gregoire
Life Sciences Technical Associate – Exit Science.
Expertise
Product Development, Manufacturing, Commercialization, Scale, Clinical trials, Regulatory, and Compliance.
Vice President of R&D and Nuclear Operations - ABK Biomedical Inc. Director - Versant Solutions Inc. Project engineer, Director – Nordion – Health and Hospitals, A Sotera Health Company
Allan Hennigar
Life Sciences, Digital technology Integration Associate – Exit Science.
Expertise
Product design and development, Operationalization, Resource management and planning, Commercialization, Product/market fit, Technical/Business integration, Business development.
Business development and R&D Lead – Kinduct. Research Manager, Division of Orthopaedic Surgery - Dalhousie University and Capital District Health Authority.
Our Advisors
Michelle Nguyen
Commercialization and marketing
Global Head, Cardiovascular Strategy – Nova Nordisk; Global Franchise Lead (Interim), Respiratory Vaccines; Global Head of Consumer, Executive Director (AVP) - Respiratory Vaccines; Global Commercial Lead, CMV, Sr. Director of Marketing - Latent Viruses - Moderna.
